Disclosed are pyrazol-1-yl-aryl carboxamides and their derivatives as represented by the general formula (I), wherein Y is a divalent, aromatic or 6-membered heteroaromatic radical which has 1 or 2 nitrogen atoms as ring members and which optionally has 1 or 2 substituents Ry: W is a radical of the formula W1 or else it forms together with R2 a tricyclic radical of the formula W6, which is linked via nitrogen and wherein the remaining substituents are as defined herein. Representative compounds include N-{ 1-[amino(oxo)acetyl]pentyl} -5-chloro-2-(3-phenyl-1H-pyrazol-1-yl)nicotinamide, N-(3-amino-1 -benzyl-2,3-dioxopropyl)-2-[3-(4-chorophenyI)-1H-pyrazol-1-yI]nicotinamide, N-(3-amino-1-benzyl-2,3-dioxopropyl)-2-(4,5-dihydro-2H-benzo[g]indazol-2-yI)nicotinamide, N-[3-amino-2,3-dioxo-1-(phenylmethyl)propyl]-2-(8-chlorochromeno[4,3-c]pyrazol-2(4H)-yI)pyridine-3-carboxamide, N-[3-amino-2,3-dioxo-1-(phenylmethyl)propyl]-2-(4,5-dihydro-2H-[1]benzoxepino[5,4-c]pyrazol-2-yI)pyridine-3-carboxamide and N-[3-amino-2,3-dioxo-1-(phenylmethyl)propyl]-2-[4-(dimethylamino)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]pyridine-3-carboxamide. Further disclosed is a medicament which comprises at least one compound, a tautomer, a prodrug or a pharmaceutically suitable salt thereof as defined above for the treatment of a disorder, an impairment or a condition which is selected from HIV, neurodegenerative disorders, epilepsy, pain, damage to the heart following cardiac ischemias, damage to the kidneys following renal ischemias, skeletal muscle damage, muscular dystrophies, damage resulting from proliferation of smooth muscle cells, coronary vasospasms, cerebral vasospasms, macular degeneration, cataracts of the eyes, restenosis of the blood vessels following angioplasty, and a disorder or an impairment associated with an elevated interleukin-I, TNF or Ab level.
